An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

Pfizer Inc.’s next-generation treatment for breast cancer posted mixed results in a final-stage study, a potential setback ...

Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising ...

Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ ...

Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased ...

"I was expecting him probably to win. It was very big win," Pfizer's CEO Albert Bourla said of President Donald Trump's ...

However, its potential is seen as being tied to the ability of the drug to target the broader population of ESR1 'wild-type' patients While Pfizer trumpeted the result as a "clinically meaningful ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

Senators ask if contracts between drugmakers and telehealth companies violate the federal anti-kickback statute.

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, describes how his company's ...